Figure 8.

GMCSF-MOG was an effective intervention that prevented progression of EAE. Mice were immunized on day 0 with 200 ug MOG35-55 in CFA plus Pertussis toxin (200 ng i.p.) on days 0 and 2. Treatment was initiated when the first mice began showing clinical signs. Mice were matched for clinical signs and were injected subcutaneously with saline or 2 nanomoles of the synthetic peptide MOG35-55 or 2 nanomoles of the GMCSF-MOG TTV (in saline) on days 13, 15, 17, and 20. Table 4 and Figure 8 represent the same experiment. Daily clinical scores for mice treated with GMCSF-MOG significantly differed from those treated with MOG35-55 (days 16-38) or saline (days 15-38). Daily clinical scores for mice treated with MOG35-55 were significantly different from those treated with saline (days 18-22, 24, 32-36).